id	author	title	date	pages	extension	mime	words	sentences	flesch	summary	cache	txt
cord-299870-4ulmbn1r	Ferrara, Giovanna	Anakinra for Treatment-Resistant Kawasaki Disease: Evidence from a Literature Review	2020-09-03		.txt	text/plain	5123	236	50	Intravenous immunoglobulin (IVIG) in association with aspirin represents the main treatment for KD, and administration of these treatments within the first 10 days following fever onset has been associated with a fivefold reduction in the risk of coronary artery aneurysms (CAA) [1] . The first report on the use of anti-IL-1 in KD dates back to 2012 [20] and described a 2-year-old boy with classic KD who developed myocarditis with reduction of the ejection fraction to 20%, without coronary artery inflammation, 2 days after the first dose of IVIG. The main reason for the use of anakinra was persistent fever (8/11), followed by gradual dilatation of the coronary arteries (7/11), persistence of clinical (2/11) or laboratory abnormalities (6/11), and severe myocarditis with KD shock syndrome in one case. This study supports the early use of anakinra in cases refractory to IVIG, demonstrating that it is quickly effective on KD symptoms, inflammation parameters, and dilatation of the coronary arteries in most patients, with good tolerability.	./cache/cord-299870-4ulmbn1r.txt	./txt/cord-299870-4ulmbn1r.txt